What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Nivolumab demonstrates a clear clinical advantage over docetaxel, particularly for patients with PD-L1-positive non-squamous NSCLC, as evidenced by statistically significant improvements in overall survival from the CheckMate 057 trial. The committee concluded that nivolumab is clinically effective compared to docetaxel alone, which supports the rating of A+.
Does the economic case hold at the expected price? — Cost effectiveness
The most plausible ICER for nivolumab compared to docetaxel was reported at £33,191 per QALY gained, which is within NICE’s acceptable range for cost-effectiveness. The committee concluded that nivolumab represents a defensible cost-effective option, supporting the A rating.
Is there quality-of-life evidence payers weigh? — Quality of life
The committee accepted a post-progression utility value of 0.569, which reflects moderate improvements in quality of life for patients receiving nivolumab. Although there were concerns about selection bias in the EQ-5D data, the overall evidence supports a moderate benefit in HRQoL, justifying the A rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Nivolumab has a very good safety profile, with mostly mild or moderate adverse events reported. The committee noted that serious adverse events were rare, which supports a rating of A+ for safety and tolerability.
Was the drug compared against what payers expect? — Comparator Selection
The committee identified docetaxel as the most appropriate comparator for nivolumab, based on current clinical practice. The evidence primarily compared nivolumab to docetaxel, which aligns with NICE’s methods for technology appraisals, justifying an A rating.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population for nivolumab included patients with PD-L1-positive non-squamous NSCLC, which is representative of the intended real-world patient population. The committee noted that the population was well-defined, supporting a rating of A+.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Nivolumab can be integrated into existing treatment pathways with minor adjustments, such as adherence to the 2-year stopping rule. The committee concluded that the integration into clinical practice is manageable, justifying an A rating.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of nivolumab is manageable, and the committee noted that it is likely to be resource-efficient given the cost-effectiveness estimates. This supports a rating of A for resource use and cost implications.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is strong, primarily derived from the CheckMate 057 trial, which is a well-designed Phase III RCT. The committee acknowledged minor limitations but overall considered the evidence robust, justifying an A+ rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the duration of treatment benefit and the stopping rule, the committee found these manageable within the context of the evidence. The overall societal context supports the use of nivolumab, justifying an A rating.
